Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

Launched by LI XIN-XIANG · Jan 23, 2018

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a treatment called adjuvant chemotherapy for patients with stage III rectal cancer who have already received another treatment called neoadjuvant chemoradiotherapy. In simpler terms, this means that the trial is looking at whether giving chemotherapy after surgery can help improve the outcome for patients who have had this type of cancer.

To participate in this trial, patients need to be between the ages of 18 and 75 and have a confirmed diagnosis of rectal cancer, which must be located within 12 centimeters of the anus. They also need to have been assessed by imaging tests like CT or MRI to ensure their cancer is at stage III and has not spread to other organs. Participants can expect to undergo treatment and regular check-ups to monitor their health. It's important to know that certain conditions, like pregnancy or severe health issues, may prevent someone from being eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The lesion must be within 12 cm of the anus as measured by endoscopy
• • Histologically confirmed diagnosis of rectal carcinoma
• • CT, MRI and EUS verified as clinical stage III rectal cancer without involvement of other organs
• • Without multiple primary cancer
• • Sufficient organ function
• • Able to provide written informed consent
• Exclusion Criteria:
• • Younger than 18 years or older than 75 years
• • Synchronous or metachronous malignancy within 5 years.
• • Patients with Intestinal obstruction or perforation or bleeding who require emergency surgery.
• • Patients with a history of pelvic irradiation.
• • ASA grade IV or V.
• • Women who are pregnant (confirmed by serum b-HCG in women of reproductive age) or breast feeding.
• • Severe mental illness.
• • Patients with severe emphysema, interstitial pneumonia, or ischemic heart disease who can not tolerate surgery.
• • Patients who received steroid therapy within one month.
• • Patients or family members misunderstand the conditions and goals of this study.